- Home
- COP vs SNY Comparison
COP vs SNY Comparison
Compare COP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COP
- SNY
- Stock Information
- Founded
- COP 1917
- SNY 1994
- Country
- COP United States
- SNY France
- Employees
- COP N/A
- SNY N/A
- Industry
- COP Integrated oil Companies
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- COP Energy
- SNY Health Care
- Exchange
- COP Nasdaq
- SNY Nasdaq
- Market Cap
- COP 119.9B
- SNY 113.4B
- IPO Year
- COP N/A
- SNY N/A
- Fundamental
- Price
- COP $93.83
- SNY $46.97
- Analyst Decision
- COP Buy
- SNY Buy
- Analyst Count
- COP 17
- SNY 4
- Target Price
- COP $120.65
- SNY $61.50
- AVG Volume (30 Days)
- COP 6.1M
- SNY 2.7M
- Earning Date
- COP 10-30-2025
- SNY 10-24-2025
- Dividend Yield
- COP 3.32%
- SNY 3.40%
- EPS Growth
- COP N/A
- SNY 118.56
- EPS
- COP 7.47
- SNY 8.65
- Revenue
- COP $59,386,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- COP $8.68
- SNY $1.53
- Revenue Next Year
- COP N/A
- SNY $7.06
- P/E Ratio
- COP $12.58
- SNY $5.43
- Revenue Growth
- COP 2.25
- SNY 15.65
- 52 Week Low
- COP $79.88
- SNY $44.73
- 52 Week High
- COP $116.08
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- COP 47.96
- SNY 43.02
- Support Level
- COP $91.69
- SNY $46.50
- Resistance Level
- COP $95.07
- SNY $47.69
- Average True Range (ATR)
- COP 2.24
- SNY 0.68
- MACD
- COP -0.26
- SNY -0.18
- Stochastic Oscillator
- COP 36.32
- SNY 36.14
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2024, it produced 2.0 million barrels per day of oil and natural gas liquids and 3.4 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2024 were 7.8 billion barrels of oil equivalent.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.